Management of Type 2 Respiratory Failure in COPD

Initial Assessment and Oxygen Therapy

The British Thoracic Society recommends arterial blood gas measurement to diagnose and quantify the severity of acute hypercapnic respiratory failure before starting treatment 1
Controlled oxygen therapy with a target saturation of 88-92% reduces mortality and the frequency and severity of acute hypercapnic respiratory failure, according to the British Thoracic Society 1
Oxygen administration should start at a low dose, such as 24% by Venturi mask or 1-2 L/min by nasal cannulae, as recommended by the European Respiratory Society 2, 3
Monitor arterial blood gases regularly and adjust oxygen doses to achieve target saturation without elevating PaCO2 by >1.3 kPa or lowering pH to <7.25, as suggested by the European Respiratory Society 2

The British Thoracic Society recommends administering nebulized bronchodilators, such as β-agonist or anticholinergic, to patients with COPD exacerbation 4
Combination therapy with both bronchodilator types may be considered for severe exacerbations or poor response to single agents, according to the British Thoracic Society 4
Systemic corticosteroids, such as prednisolone 30 mg/day, may be considered for 7-14 days in patients with COPD exacerbation, as recommended by the British Thoracic Society 4

The British Thoracic Society recommends starting NIV when pH <7.35, PaCO2 ≥6.5 kPa, and respiratory rate >23 breaths/min persists after one hour of optimal medical therapy 5
NIV should be considered for patients with PaCO2 between 6.0 and 6.5 kPa, according to the British Thoracic Society 5
Document an individualized patient plan at the start of treatment regarding measures to be taken if NIV fails, as recommended by the British Thoracic Society 1

The British Thoracic Society recommends considering invasive intermittent positive pressure ventilation (IPPV) in patients with pH <7.26 and rising PaCO2 who fail to respond to NIV and controlled oxygen therapy 4
Factors favoring IPPV use include first episode of respiratory failure, acceptable quality of life/activity level, and identifiable reversible cause, according to the British Thoracic Society 4

The European Respiratory Society recommends long-term oxygen therapy (LTOT) for at least 15 hours/day to improve survival in patients with chronic respiratory failure 2, 3
LTOT criteria include stable respiratory failure with PaO2 ≤7.3 kPa despite optimal therapy, as recommended by the European Respiratory Society 2, 3
Pulmonary rehabilitation improves exercise tolerance and quality of life in patients with COPD, according to the European Respiratory Society 6

Regularly monitor arterial blood gases to assess response to therapy, as recommended by the British Thoracic Society 1
Assess for and treat reversible causes contributing to respiratory failure, according to the British Thoracic Society 1
Evaluate the need for long-term oxygen therapy after stabilization, as recommended by the European Respiratory Society 2, 3

The European Respiratory Society recommends giving prednisolone 30 mg/day for 7-14 days in patients with COPD exacerbation, as systemic corticosteroids reduce treatment failure and improve outcomes 7
The British Thoracic Society suggests prescribing antibiotics when two or more cardinal symptoms are present, such as increased dyspnea, increased sputum volume, or purulent sputum, as antibiotic therapy reduces short-term mortality by 77% and treatment failure by 53% 8
The European Respiratory Society recommends choosing antibiotics based on local resistance patterns, with typical options including amoxicillin/clavulanate, macrolides, or tetracyclines, and the duration of antibiotic therapy should be 5-7 days 7

The European Respiratory Society recommends admitting patients with marked increase in dyspnea unresponsive to outpatient management, worsening hypoxemia or hypercapnia, changes in mental status, high-risk co-morbidities, or inability to eat, sleep, or self-care due to symptoms 7

The European Respiratory Society suggests transferring patients to ICU or specialized respiratory care unit for impending or actual respiratory failure, other end-organ dysfunction, or hemodynamic instability 7

The British Thoracic Society recommends assessing for long-term oxygen therapy (LTOT) before discharge by checking ABGs on room air, and LTOT criteria include PaO2 ≤7.3 kPa or SaO2 ≤88% despite optimal therapy, confirmed twice over 3 weeks 9

The British Thoracic Society suggests checking FEV1 measurement, peak flow twice daily until clinically stable, and ABGs on room air in patients who presented with hypercapnic respiratory failure before discharge 9
The British Thoracic Society recommends transitioning nebulized bronchodilators to usual inhaler at least 24-48 hours before discharge as clinical condition improves 9

The British Thoracic Society recommends stopping oral corticosteroids abruptly after 7 days unless there are specific reasons for long-term use, and antibiotics typically do not need continuation beyond 7 days 9